S1PR1 and myeloid sarcoma: The following drugs were used: GA (Copaxone) FP n = 6, LP n = 2; dimethyl fumarate (Tecfidera) FP n = 2, LP n = 1; natalizumab (Tysabri) FP n = 1, LP n = 0; interferons β1a (Avonex, Rebif, Plegridy FP n = 6, LP n = 5); inhibitors of the sphingosine-1-phosphate receptor (S1PR) (Ponvory, Zeposia) FP n = 5, LP n = 1; teriflunomide (Aubagio) FP n = 3, LP n = 0; ofatumumab (Kesimpta) FP n = 7, LP n = 1; ocrelizumab (Ocrevus) FP n = 11, LP n = 5; MS patients in Stage 1 without medication FP n = 2, LP n = 2.